Trenbolone: long ester
Parabolan
Parabolan after one dose: 50% at ~8 days, 25% at 16 days, 12.5% at 24 days.
Drawn from the half-life in the app's model, ~8 days. The model's figures
- Compound
- Parabolan
- Symbol
- PBL
- Family
- Other steroids
- Parts
- 13
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
Overview
PubChem lists Parabolan among the synonyms of trenbolone cyclohexylmethylcarbonate, which it also names trenbolone hexahydrobenzyl carbonate.1 The record gives the molecular formula C26H34O4 and a molecular weight of 410.5 g/mol.1
Tauchen and colleagues, writing from the Czech University of Life Sciences Prague and the University of Chemistry and Technology Prague (Molecules, 2021), state that trenbolone "has been marketed as a variety of esters, many of which are no longer used in veterinary or medicinal practice."2 The same review states: "Perhaps the most common trenbolone ester for human use was hexahydrobenzylcarbonate, but this is no longer prescribed."2 Its Table 1, on medicinal use and usual routes of administration, lists wasting syndromes for trenbolone, noted as "now discontinued in most countries", and lists the acetate and hexahydrobenzylcarbonate esters under intramuscular injection.2
Sources do not use the brand name for one ester consistently.3,4,5 A 2006 case report from the Medical University of Gdańsk (Anand and colleagues, ASAIO Journal) wrote "Parabolan (trenbolone acetate)", and a 2023 scoping review by Solanki and colleagues (Endocrine Connections) lists Parabolan among the trade names in its trenbolone acetate row.3,4 Mullen and colleagues (British Journal of Pharmacology, 2020) list Parabolan against trenbolone hexahydrobenzylcarbonate.5
Fuchs and colleagues (Maastricht University Medical Centre+, Medicine and Science in Sports and Exercise, 2026) used MRI to measure skeletal muscle and visceral organ volumes in 45 men: 15 recreationally active controls, 15 natural bodybuilders and 15 competitive male bodybuilders who reported using appearance- and performance-enhancing drugs.6 Their self-reported drug table has a 19-nortestosterone derivatives row naming nandrolone decanoate, nandrolone phenylpropionate, trenbolone enanthate, trenbolone acetate and trenbolone hexahydrobenzylcarbonate, reported by 7 of the 15 drug-using bodybuilders (46.7%).6 The table does not give a count for any one agent in that row, so it does not show how many of the 15 drug-using bodybuilders used this ester.6
A search of PubMed on 16 November 2026 (titles, summary text and index terms, not full text) for hexahydrobenzylcarbonate returned 0 records, and a search for parabolan returned 1 record, the 2006 case report described below.3 A full-text search of Europe PMC on the same day returned 6 records for hexahydrobenzylcarbonate and 1 for hexahydrobenzyl carbonate. Those records were not screened one by one, so their content is not described here. ClinicalTrials.gov returned 0 studies for trenbolone and 0 for Parabolan as an intervention.
How it works
Sources in this part
What the sources say about esters in general
Kicman (British Journal of Pharmacology, 2008) describes parenteral anabolic steroid preparations as a group: the 17β-hydroxyl group is usually esterified, and "Once in the circulation, hydrolysis rapidly occurs by the action of blood esterases to yield the active compound."7 The review adds that "In general, the longer the chain length, the more slowly the preparation is released into circulation, thus prolonging the duration of action."7 The sentence listing esters names acetate for trenbolone; the Figure 3 caption of the same review lists hexahydrobenzylcarbonate among the 17β-hydroxyl-esterified preparations.7
What the sources say about trenbolone itself
Yarrow, McCoy and Borst (Steroids, 2010) reviewed trenbolone (17β-hydroxyestra-4,9,11-trien-3-one) and not this ester.8 The record is the PubMed summary of the review, and its statements concern receptor binding and mammalian species. It states that trenbolone "may be capable of inducing SARM-like effects as it binds to androgen receptors (ARs) with approximately three times the affinity of testosterone and has been shown to augment skeletal muscle mass and bone growth and reduce adiposity in a variety of mammalian species."8 The summary also states that trenbolone "is metabolized to less potent androgens in vivo", whereas testosterone undergoes biotransformation to more potent steroids, dihydrotestosterone and 17β-estradiol, through the 5α-reductase and aromatase enzymes.8 It adds that, compared with testosterone, trenbolone "appears to induce less growth in androgen-sensitive organs which highly express the 5alpha reductase enzyme".8 Fuchs and colleagues place the hexahydrobenzylcarbonate ester among the 19-nortestosterone derivatives.6
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~8 days
- Bioavailability
- 95%
- Typical dose
- 50–400 mg/week
- Route
- IM
- Time to peak
- ~60 h
Sources in this part
The app's figures for this ester are a half-life of about 8 days (192 h), bioavailability of 95%, a time to peak of about 60 h and the intramuscular route. None of the references gives a measured half-life, bioavailability or time to peak for this ester. A search of PubMed on 16 November 2026 for trenbolone with pharmacokinetics or half-life in the title or summary text returned 8 records, and a search for hexahydrobenzylcarbonate alone returned 0 records, so none of the 8 names it in its title, summary text or index terms; the full text of the 8 was not checked.
| Parameter | App's figure | Reported in the references |
|---|---|---|
| Half-life | ~8 days (192 h) | No measured value |
| Bioavailability | 95% | No measured value |
| Time to peak | ~60 h | No measured value |
| Route | IM | Intramuscular injection listed for the acetate and hexahydrobenzylcarbonate esters2 |
Human studies
In the PubMed and ClinicalTrials.gov searches listed above, no record was identified as a clinical trial, registry entry or pharmacokinetic study of the ester; the Europe PMC full-text records were not screened one by one. The one PubMed record that matches the brand name is a single-patient case report, which names the product as trenbolone acetate.3
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Anand and colleagues, 20063 | Case report, Medical University of Gdańsk | 1 man, 21 years, bodybuilder, no previous medical history | Dose and duration not stated; described as an overdose of "Parabolan (trenbolone acetate)" | Pruritus and yellow discoloration of skin and sclerae; cholestasis with serum bilirubin up to 65.5 mg/dl; five MARS cycles of 8 to 12 hours every second day; plasma bilirubin 2 mg/dl at the 2-month visit |
Sources in this part
Deeper analysis: the 2006 cholestasis case report
Anand and colleagues, of the Clinic of Internal Medicine and Acute Poisonings at the Medical University of Gdańsk, described one 21-year-old male bodybuilder who "overdosed on Parabolan (trenbolone acetate) because of its anabolic activity."3 He had pruritus and yellow discoloration of the skin and sclerae, and laboratory examination showed signs of cholestasis with a serum bilirubin level of up to 65.5 mg/dl.3 "Because supportive medical treatment was ineffective", he was treated with the molecular adsorbent recirculating system, in five cycles of 8 to 12 hours every second day.3 The report states that the procedure "was well tolerated by the patient and resulted in a sustained relief of pruritus" and that plasma bilirubin had decreased to 2 mg/dl at the 2-month follow-up visit.3 The PubMed record gives no dose, duration of use, funding statement or stated limitations, and it describes one patient with no comparator.3 Because the authors name the product as trenbolone acetate, the case is not evidence about the hexahydrobenzylcarbonate ester.3
Analysis of seized injectable products
Balayssac and colleagues (Université de Toulouse, Molecules, 2025) analysed 12 oil-based injectable formulations obtained from French gendarmerie seizures by 13C NMR, 1H NMR and mass spectrometry.9 Two of the 12, labelled OI-11 and OI-12, claimed testosterone enanthate, trenbolone acetate and trenbolone hexahydrobenzyl carbonate at 75 mg/mL each.9 The only steroid detected in them was testosterone propionate, at 34 ± 2 mg/mL in OI-11 and 48 ± 1 mg/mL in OI-12.9
| Sample | Claimed content (mg/mL) | Detected (mg/mL) | Study |
|---|---|---|---|
| OI-11 | Testosterone enanthate 75; trenbolone acetate 75; trenbolone hexahydrobenzyl carbonate 75 | Testosterone propionate 34 ± 2 | Balayssac and colleagues, 20259 |
| OI-12 | Testosterone enanthate 75; trenbolone acetate 75; trenbolone hexahydrobenzyl carbonate 75 | Testosterone propionate 48 ± 1 | Balayssac and colleagues, 20259 |
Sources in this part
Deeper analysis: Balayssac and colleagues, 2025
The authors write that for the 12 oil-based formulations, "none of the samples are qualitatively in compliance with the stated composition".9 For seven samples the active ingredients differed from those announced, and in the other five only 1 of 2, 1 of 3 or 2 of 3 listed steroids were present.9 The authors report no correlation of the 12 formulations with the trenbolone pattern (Pearson coefficient below -0.06, given as one value "for trenbolone" and not for OI-11 and OI-12 alone) and conclude that their composition relies on at least one of the testosterone esters propionate, enanthate and cypionate.9 The authors state that "This research received no external funding" and declare no conflicts of interest.9 They write that the chemometric approach, "although tested on a limited number of samples, faces limitations in terms of statistical significance and generalizability", and that "the low sensitivity of NMR, especially 13C, can be a limitation", while adding that for potential fake formulations this "is not a major concern".9 The result describes two seized products and says nothing about the content of any pharmaceutical product named Parabolan.9
Doses reported in reviews
Sources in this part
No trial or label reporting a dose of this ester was identified in the PubMed, ClinicalTrials.gov and DailyMed searches listed above; DailyMed covers US labels only. Two reviews tabulate weekly doses for this ester, and their figures differ from each other and from the app's range of 50–400 mg/week.5,10
| Source | Figure for this ester | Basis stated by the source |
|---|---|---|
| The app | 50–400 mg/week | The app's typical dose range |
| McCullough and colleagues, 202110 | 150–230 mg typical weekly dose | Table 1, a list of injectable and oral anabolic steroids and typical doses used |
| Mullen and colleagues, 20205 | 300–500 mg per week under the heading "Recommended effective dose (online community)" in the male column; "Not recommended" in the female column | Information that "comes from online user reports and supplier marketing information" |
McCullough and colleagues (Liverpool John Moores University, Reviews in Endocrine and Metabolic Disorders, 2021) declare no conflict of interest, and one author's PhD studentship was funded by Liverpool John Moores University.10 Mullen and colleagues (University of the West of Scotland and other institutions) declare no conflicts of interest.5 McCullough and colleagues cite two reviews for their table, Kicman (2008) and De Souza and Hallak (2011), and Mullen and colleagues name online user reports and supplier marketing information as the source of theirs.5,10 Neither table names a trial or label for the figure it gives for this ester.5,10
Side effects reported
Sources in this part
In the searches listed above, no record was identified as a study of this ester reporting side effects in a measured group. Tauchen and colleagues write about trenbolone as a whole that "Among other relatively common side-effects of trenbolone use are erectile dysfunction, reduced sex drive, night sweats, insomnia, increased aggressivity, anxiety, and cardiovascular problems."2 The review also describes "an orange coloration of body fluids, including urine", which it calls "A harmless, but potentially worrying adverse effect of trenbolone", and a "trenbolone cough", "particularly prevalent in trenbolone acetate", whose mechanism it says "has not yet been satisfactorily explained".2 It gives these as statements about trenbolone, not about the hexahydrobenzylcarbonate ester.2
The single case report that names Parabolan describes cholestasis with serum bilirubin up to 65.5 mg/dl in a 21-year-old man, and it names the product as trenbolone acetate.3
Regulatory and anti-doping status
The WADA 2026 Prohibited List, in effect from 1 January 2026, places anabolic agents in section S1, prohibited at all times in and out of competition, and states that "All prohibited substances in this class are non-Specified Substances."11 Section S1.1 is headed "When administered exogenously, including but not limited to", lists trenbolone among the anabolic androgenic steroids and ends: "and other substances with a similar chemical structure or similar biological effect(s) including their esters."11 The text of the list does not name Parabolan or hexahydrobenzylcarbonate.11 Whether the ester falls under that wording is a legal reading that the references do not give.
In the United States, 21 CFR 1308.13(f) places anabolic steroids in Schedule III, "including its salts, esters and ethers", and its list includes "trenbolone (17β-hydroxyestr-4,9,11-trien-3-one)". The paragraph begins "Unless specifically excepted or unless listed in another schedule, any substance meeting the definition of anabolic steroid as set forth in § 1300.01 of this chapter".12 The text of that section does not name Parabolan or hexahydrobenzylcarbonate.12 Whether the ester falls under that wording is a legal reading that the references do not give.
A DailyMed search on 16 November 2026 for trenbolone returned 22 label records, and each title names a trenbolone acetate product, either an implant or a powder. Searches for parabolan and for hexahydrobenzylcarbonate returned 0 labels. DailyMed holds US labels only, so these searches say nothing about other countries. Tauchen and colleagues state that the ester "is no longer prescribed", in a sentence that gives no country or date.2 They also write that "Trenbolone acetate is still used in animals to stimulate muscle growth and appetite".2
What is not known
The references report no measured half-life, bioavailability, time to peak or dose-response for this ester, and no label for it was returned by the DailyMed search of US labels. The one case report that uses the brand name calls the product trenbolone acetate, and the product analysis that lists the ester covers two seized samples among 12, and its correlation figure for the trenbolone pattern (below -0.06) is given for the 12 formulations together.3,9 The tables in the two reviews name no trial or label for their dose figures.5,10 The references give no year of approval or withdrawal for the ester, and regulators other than WADA and US federal scheduling are not covered.
Frequently asked questions
What is Parabolan?
What is the half-life of Parabolan?
The app lists a half-life of about 8 days (192 h) for trenbolone hexahydrobenzylcarbonate. None of the references reports a measured half-life for this ester, and a search of PubMed on 16 November 2026 for trenbolone with pharmacokinetics or half-life returned 8 records, none naming hexahydrobenzylcarbonate in its title, summary text or index terms (full text not checked).
Is Parabolan the same as trenbolone acetate?
Is Parabolan still prescribed?
Tauchen and colleagues (2021) wrote: "Perhaps the most common trenbolone ester for human use was hexahydrobenzylcarbonate, but this is no longer prescribed."2 The sentence gives no country or date.2 A DailyMed search on 16 November 2026 returned 0 labels for parabolan or hexahydrobenzylcarbonate, and DailyMed holds US labels only.
Is Parabolan banned by WADA?
The WADA 2026 Prohibited List names trenbolone in section S1.1, prohibited at all times, and extends the entry to similar substances "including their esters".11 The section is headed "When administered exogenously, including but not limited to".11 The list text does not name Parabolan or the hexahydrobenzylcarbonate ester, and whether the ester falls under that wording is a legal reading that the references do not give.11
Is Parabolan a controlled substance in the United States?
21 CFR 1308.13(f) lists trenbolone among the Schedule III anabolic steroids, "including its salts, esters and ethers".12 It applies "Unless specifically excepted or unless listed in another schedule".12 The text does not name Parabolan or the hexahydrobenzylcarbonate ester, and whether the ester falls under that wording is a legal reading that the references do not give.12
Has Parabolan been studied in people?
What side effects are reported for Parabolan?
In the searches listed above, no record was identified as a study of the ester reporting side effects in a measured group. Tauchen and colleagues list erectile dysfunction, reduced sex drive, night sweats, insomnia, increased aggressivity, anxiety and cardiovascular problems as relatively common side-effects of trenbolone use.2
What did one analysis of seized injectables claiming this ester find?
In one analysis, two seized injectables that claimed trenbolone hexahydrobenzyl carbonate at 75 mg/mL showed testosterone propionate at 34 ± 2 and 48 ± 1 mg/mL, and the authors wrote that "no other AAS appears to be present in these formulations".9 They also wrote that "the low sensitivity of NMR, especially 13C, can be a limitation".9 The result covers two samples that are described by their claimed ingredients and not by a brand name, and it says nothing about any product named Parabolan.9 Balayssac and colleagues (2025) analysed 12 oil-based injectables from French seizures and wrote that none was qualitatively in compliance with the stated composition.9
More in Other steroids
References
- PubChem. Trenbolone cyclohexylmethylcarbonate, compound record CID 20055297. National Library of Medicine, consulted 16 November 2026. PubChem CID 20055297
- Tauchen J, Jurášek M, Huml L, Rimpelová S. Medicinal Use of Testosterone and Related Steroids Revisited. Molecules 2021. PMC7919692
- Anand JS, Chodorowski Z, Hajduk A, Waldman W. Cholestasis induced by parabolan successfully treated with the molecular adsorbent recirculating system. ASAIO J 2006. PMID 16436902
- Solanki P, Eu B, Smith J, Allan C, Lee K. Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review. Endocr Connect 2023. PMC10620455
- Mullen C, Whalley BJ, Schifano F, Baker JS. Anabolic androgenic steroid abuse in the United Kingdom: An update. Br J Pharmacol 2020. PMC7174889
- Fuchs CJ, Brauwers B, Trommelen J, et al. When Size Goes Inside: Visceromegaly in Bodybuilders Is Not Attributed to High-Protein Intake but More Likely Associated with the Use of Appearance- and Performance-Enhancing Drugs. Med Sci Sports Exerc 2026. PMC13446919
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008. PMC2439524
- Yarrow JF, McCoy SC, Borst SE. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids 2010. PMID 20138077
- Balayssac S, Assemat G, Danoun S, Malet-Martino M, Gilard V. Quantitative 1H and 13C NMR and Chemometric Assessment of 13C NMR Data: Application to Anabolic Steroid Formulations. Molecules 2025. PMC12074264
- McCullough D, Webb R, Enright KJ, et al. How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health. Rev Endocr Metab Disord 2021. PMC8087567
- World Anti-Doping Agency. Prohibited List 2026 (in effect 1 January 2026). WADA 2026. WADA 2026 list
- US Drug Enforcement Administration. Schedules of controlled substances: Schedule III, 21 CFR 1308.13. Electronic Code of Federal Regulations, consulted 16 November 2026. 21 CFR 1308.13